Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.onehlt.2021.100214 http://scihub22266oqcxt.onion/10.1016/j.onehlt.2021.100214 33426262!7784546!33426262     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33426262&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       One+Health 2021 ; 12 (ä): 100214 Nephropedia Template TP {{tp|p=33426262|t=2021. Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 |pdf=|usr=}}{{33426262}} gab.com Text Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 JO: One Health http://www.kidney.de/pget.php?&tw=1&pmid=33426262 #FOAvip BACKGROUND: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. METHODS: Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30?days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48?h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders. RESULTS: There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48?h of treatment, was not significantly different between groups (tocilizumab: -0.04; control: 0.09; p?=?0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p?=?0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p?=?0.990). CONCLUSIONS: We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48?h of treatment, or time to discharge. Twit Text FOAVip Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 ????One Health http://www.kidney.de/pget.php?&tw=1&pmid=33426262 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33426262 #FOAvip English Wikipedia <ref>{{Cite pmid|33426262}}</ref> Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 #MMPMID33426262 Rodriguez-Molinero A; Perez-Lopez C; Galvez-Barron C; Minarro A; Macho O; Lopez GF; Robles MT; Dapena MD; Martinez S; Rodriguez E; Perez IC One Health 2021[Jun]; 12 (ä): 100214 PMID33426262show ga BACKGROUND: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement. METHODS: Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30?days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48?h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders. RESULTS: There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48?h of treatment, was not significantly different between groups (tocilizumab: -0.04; control: 0.09; p?=?0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p?=?0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p?=?0.990). CONCLUSIONS: We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48?h of treatment, or time to discharge. äMatched cohort study on the efficacy of tocilizumab in patients with C(epmc).pdf DeepDyve Pubget Overpricing